Randomized Clinical Comparison of the Dual Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent with the Sirolimus-Eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention: The SORT OUT X Trial
The dual therapy sirolimus-eluting and CD34+ antibody-coated Combo stent (DTS) was designed to further improve early healing. The SORT OUT X trial was a large-scale randomized, multicenter, single-blind, two-arm, non-inferiority trial. The primary endpoint was a composite of cardiac death, myocardial infarction. The DTS did not confirm non-inferiority to the SES for target lesion failure at 12 months in an all-comer population.